Example of Journal for ImmunoTherapy of Cancer format
Recent searches

Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format Example of Journal for ImmunoTherapy of Cancer format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access
recommended Recommended

Journal for ImmunoTherapy of Cancer — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Pharmacology #17 of 297 up up by 9 ranks
Oncology #34 of 340 up up by 15 ranks
Molecular Medicine #19 of 167 up up by 6 ranks
Immunology and Allergy #26 of 182 up up by 5 ranks
Cancer Research #31 of 207 up up by 14 ranks
Immunology #32 of 202 up up by 6 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 1088 Published Papers | 11326 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 27/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Springer

Quality:  
High
CiteRatio: 9.4
SJR: 2.389
SNIP: 1.226
open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 8.2
SJR: 1.864
SNIP: 1.641
open access Open Access

Springer

Quality:  
High
CiteRatio: 5.5
SJR: 1.112
SNIP: 0.926
open access Open Access
recommended Recommended

Springer

Quality:  
High
CiteRatio: 7.7
SJR: 1.219
SNIP: 0.854

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

10.4

21% from 2019

CiteRatio for Journal for ImmunoTherapy of Cancer from 2016 - 2020
Year Value
2020 10.4
2019 8.6
2018 9.0
2017 8.3
2016 6.1
graph view Graph view
table view Table view

5.06

21% from 2019

SJR for Journal for ImmunoTherapy of Cancer from 2016 - 2020
Year Value
2020 5.06
2019 4.194
2018 3.337
2017 2.798
2016 2.668
graph view Graph view
table view Table view

2.281

26% from 2019

SNIP for Journal for ImmunoTherapy of Cancer from 2016 - 2020
Year Value
2020 2.281
2019 1.817
2018 1.452
2017 1.255
2016 1.083
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 21% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has increased by 21% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 26% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Journal for ImmunoTherapy of Cancer

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

Journal for ImmunoTherapy of Cancer

Approved by publishing and review experts on SciSpace, this template is built as per for Journal for ImmunoTherapy of Cancer formatting guidelines as mentioned in Springer author instructions. The current version was created on and has been used by 954 authors to write and format their manuscripts to this journal.

i
Last updated on
27 Jun 2020
i
ISSN
1606-8610
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
White faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Citation Type
Numbered
[25]
i
Bibliography Example
Blonder, G.E., Tinkham, M., Klapwijk, T.M.: Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B 25(7), 4515–4532 (1982)

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1186/S40425-017-0300-Z
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Abstract:

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms re... Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently. The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the literature, and treatment-related deaths occur in up to 2% of patients, varying by ICI. Immunotherapy-related irAEs typically have a delayed onset and prolonged duration compared to adverse events from chemotherapy, and effective management depends on early recognition and prompt intervention with immune suppression and/or immunomodulatory strategies. There is an urgent need for multidisciplinary guidance reflecting broad-based perspectives on how to recognize, report and manage organ-specific toxicities until evidence-based data are available to inform clinical decision-making. The Society for Immunotherapy of Cancer (SITC) established a multidisciplinary Toxicity Management Working Group, which met for a full-day workshop to develop recommendations to standardize management of irAEs. Here we present their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy. read more read less

Topics:

Immunotherapy (50%)50% related to the paper
View PDF
1,325 Citations
open accessOpen access Journal Article DOI: 10.1186/S40425-018-0343-9
Cytokine release syndrome

Abstract:

During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T cells have shown remarka... During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T cells have shown remarkable efficacy in clinical trials and some of these agents have already received regulatory approval. However, along with growing experience in the clinical application of these potent immunotherapeutic agents comes the increasing awareness of their inherent and potentially fatal adverse effects, most notably the cytokine release syndrome (CRS). This review provides a comprehensive overview of the mechanisms underlying CRS pathophysiology, risk factors, clinical presentation, differential diagnoses, and prognostic factors. In addition, based on the current evidence we give practical guidance to the management of the cytokine release syndrome. read more read less

Topics:

Cytokine release syndrome (58%)58% related to the paper, Cytokine storm (54%)54% related to the paper, Chimeric antigen receptor (53%)53% related to the paper, Immune checkpoint (52%)52% related to the paper, Immunotherapy (51%)51% related to the paper
View PDF
1,056 Citations
open accessOpen access Journal Article DOI: 10.1186/S40425-018-0316-Z
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
Jun Gong1, Alexander Chehrazi-Raffle2, Srikanth Reddi2, Ravi Salgia1

Abstract:

Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antigen-specific T-cell immunity. Early-p... Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antigen-specific T-cell immunity. Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014. The number of FDA-approved agents of this class is rapidly enlarging with indications for treatment spanning across a spectrum of malignancies. The purpose of this review is to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy to date. In particular, we focus on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies in cancer. As the number of PD-1/PD-L1 inhibitors continues to grow, predictive biomarkers, mechanisms of resistance, hyperprogressors, treatment duration and treatment beyond progression, immune-related toxicities, and clinical trial design are key concepts in need of further consideration to optimize the anticancer potential of this class of immunotherapy. read more read less

Topics:

Pembrolizumab (62%)62% related to the paper, Nivolumab (56%)56% related to the paper, Cancer immunotherapy (53%)53% related to the paper, Clinical study design (50%)50% related to the paper, Cancer (50%)50% related to the paper
View PDF
867 Citations
open accessOpen access Journal Article DOI: 10.1186/S40425-017-0257-Y
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

Abstract:

The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeti... The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeting either the ligands or the receptor are currently in clinical development. Emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile, making them attractive combination partners for both standard treatment modalities and immunotherapeutic agents. The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion. In the malignant disease setting, data on the clinical activity of immunotherapy combinations with CSF1/CSF1R-targeting agents are pending. As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily influenced by a continuum of survival, differentiation, recruitment, and polarization signals within their specific tissue environment. Thus, the role of macrophages in regulating tumorigenesis and the impact of depleting and/or reprogramming TAM as therapeutic approaches for cancer patients may vary greatly depending on organ-specific characteristics of these cells. We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies. Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impact on CSF1/CSF1R-targeting treatment strategies for the future. read more read less

Topics:

Colony stimulating factor 1 receptor (55%)55% related to the paper, Tumor-associated macrophage (51%)51% related to the paper
View PDF
605 Citations
open accessOpen access Journal Article DOI: 10.1136/JITC-2019-000337
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Abstract:

Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. ... Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation. read more read less

Topics:

Immunogenic cell death (58%)58% related to the paper, Acquired immune system (53%)53% related to the paper, Pattern recognition receptor (50%)50% related to the paper
View PDF
544 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Journal for ImmunoTherapy of Cancer.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Journal for ImmunoTherapy of Cancer in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Journal for ImmunoTherapy of Cancer guidelines and auto format it.

2. Do you follow the Journal for ImmunoTherapy of Cancer guidelines?

Yes, the template is compliant with the Journal for ImmunoTherapy of Cancer guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Journal for ImmunoTherapy of Cancer?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Journal for ImmunoTherapy of Cancer citation style.

4. Can I use the Journal for ImmunoTherapy of Cancer templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Journal for ImmunoTherapy of Cancer.

5. Can I use a manuscript in Journal for ImmunoTherapy of Cancer that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Journal for ImmunoTherapy of Cancer that you can download at the end.

6. How long does it usually take you to format my papers in Journal for ImmunoTherapy of Cancer?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Journal for ImmunoTherapy of Cancer.

7. Where can I find the template for the Journal for ImmunoTherapy of Cancer?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Journal for ImmunoTherapy of Cancer's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Journal for ImmunoTherapy of Cancer's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Journal for ImmunoTherapy of Cancer an online tool or is there a desktop version?

SciSpace's Journal for ImmunoTherapy of Cancer is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Journal for ImmunoTherapy of Cancer?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Journal for ImmunoTherapy of Cancer?”

11. What is the output that I would get after using Journal for ImmunoTherapy of Cancer?

After writing your paper autoformatting in Journal for ImmunoTherapy of Cancer, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Journal for ImmunoTherapy of Cancer's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Journal for ImmunoTherapy of Cancer?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Journal for ImmunoTherapy of Cancer. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Journal for ImmunoTherapy of Cancer?

The 5 most common citation types in order of usage for Journal for ImmunoTherapy of Cancer are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Journal for ImmunoTherapy of Cancer?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Journal for ImmunoTherapy of Cancer's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Journal for ImmunoTherapy of Cancer in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Journal for ImmunoTherapy of Cancer Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Journal for ImmunoTherapy of Cancer formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template